39 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
ARRY Array BioPharma Inc. $17.19 $3.57B Buy
Article Searches
Array BioPharma: Expecting Significant Upside In 2018 https://seekingalpha.com/article/4129177-array-biopharma-expecting-significant-upside-2018?source=feed_all_articles Dec 02, 2017 - Shares have risen a decent bit since my initial entries, but I believe 2018 holds substantially more upside ahead.Below I provide a recap of the bullish thesis and recent events.After its September se
Are Options Traders Betting on a Big Move in Array BioPharma (ARRY) Stock? http://www.zacks.com/stock/news/285513/are-options-traders-betting-on-a-big-move-in-array-biopharma-arry-stock?cid=CS-ZC--285513 Dec 11, 2017 - Investors need to pay close attention to Array BioPharma (ARRY) stock based on the movements in the options market lately.
ROTY Edition 1 Volume 64: Several Key Updates And Trades https://seekingalpha.com/article/4132706-roty-edition-1-volume-64-several-key-updates-trades?source=feed_tag_etf_portfolio_strategy Dec 19, 2017 - While performance for December continues to disappoint, we continue to position the ROTY model account for a profitable 2018.Argenx received a very large price hike from an analyst.Global Blood Therap
Array Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares http://www.gurufocus.com/news/612900/array-biopharma-inc-arry-ceo-ron-squarer-sold-89-million-of-shares Dec 19, 2017 - Array Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares, Stocks: ARRY, release date:Dec 19, 2017
ROTY Edition 1 Volume 65: My Recent Interview And Promising Updates On Holdings https://seekingalpha.com/article/4133344-roty-edition-1-volume-65-recent-interview-promising-updates-holdings?source=feed_tag_etf_portfolio_strategy Dec 21, 2017 - I remind readers to check out  my recent interview with Seeking Alpha Editor Steve Brown for my thoughts on the year ahead and themes that could work.Perceptive Advisors' stake in Global Blood Therape
Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL https://seekingalpha.com/article/4133858-daily-pharma-scoop-amgen-plans-bring-back-cash-roche-acquires-ignyta-agile-tumbles-crl?source=feed_sector_healthcare Dec 26, 2017 - Amgen plans to repatriate some of its cash holdings kept outside the U.S. Roche acquired Ignyta, paying premium of more than 70%. Agile tumbled nearly 50% on CRL.
Your Daily Pharma Scoop: Ardelyx Reports Data, Omeros Moves Forward With OMS721, Allergan Announces Job Cuts https://seekingalpha.com/article/4135192-daily-pharma-scoop-ardelyx-reports-data-omeros-moves-forward-oms721-allergan-announces-job?source=feed_sector_healthcare Jan 04, 2018 - Ardelyx announced a significant drop in diarrhea incidence. Omeros reached an agreement with FDA on design of Phase 3 trial for OMS 721 in IgN. Allergan announced that it will cut more than 1,000 jobs
Array BioPharma (ARRY) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow https://seekingalpha.com/article/4136343-array-biopharma-arry-presents-36th-annual-j-p-morgan-healthcare-conference-slideshow?source=feed_all_articles Jan 09, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with this event.
ARRY: Stifel reits Buy http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180122072505 Jan 22, 2018 - Stifel issues rating change for ARRY
Researchers 'very excited' over Array BioPharma's cancer drug trial results http://feeds.bizjournals.com/~r/industry_7/~3/4DD2mPrxSp4/researchers-very-excited-over-array-bioharmas.html Jan 22, 2018 - Researchers say they are "very excited" about the clinical results of Array BioPharma Inc.'s metastatic colorectal cancer drug. The Boulder biotech announced Saturday that in a clinical test of 30 patients, the results showed "substantial improvements compared to several separate historical published standard of care benchmarks for this population." "We are very excited about these safety lead-in results, which show both an unprecedented progression-free survival and overall response rate in patients…

Pages: 1234

Page 1>

Related Companies

Name Exchange Price Mkt Cap
BPMC Blueprint Medicines Corporation NASDAQ $81.84 $3.56B
TSRO TESARO, Inc. NASDAQ $62.3 $3.39B
GWPH GW Pharmaceuticals Plc NASDAQ $130.83 $3.32B
LGND Ligand Pharmaceuticals Incorporated NASDAQ $155.51 $3.28B
ACAD ACADIA Pharmaceuticals Inc. NASDAQ $31.05 $3.86B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Array BioPharma
ARRY - Google Finance https://www.google.com/finance?q=ARRY Industry related info and international coverage Summary News
ARRY - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=ARRY Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options